Supriya Lifescience Limited
NSE: SUPRIYA · Pharmaceuticals
Snapshot
Unlock Supriya Lifescience Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Supriya Lifescience Limited is a Mumbai-based pharmaceutical company specialising in the research, development, and manufacturing of active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio including anti-histamine, anti-asthmatic, and analgesic therapeutic segments for global markets.
Business Model
The company generates revenue primarily through the large-scale production and sale of bulk drugs and APIs to international pharmaceutical manufacturers. It leverages its research and development capabilities to supply a wide range of therapeutic categories and chemical derivatives.
Growth Outlook
Growth is driven by the expansion of its API product pipeline and the strengthening of its global distribution network. The company continues to focus on enhancing its manufacturing capabilities to meet increasing international demand for specialised pharmaceutical ingredients.
Key Risks
- Regulatory Compliance. The company is subject to stringent inspections by global health authorities, where any failure to meet quality standards could lead to export restrictions.
- Raw Material Price Volatility. Fluctuations in the costs of key starting materials and chemical intermediates can significantly impact operating margins.
- Foreign Exchange Risk. As a significant portion of revenue is derived from international markets, the company is exposed to currency fluctuations between the Indian Rupee and foreign currencies.
- Geopolitical and Trade Barriers. Changes in international trade policies or import regulations in key markets could disrupt the company's supply chain and sales volume.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Supriya Lifescience Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹828 Cr
TTM · standalone
NET PROFIT
₹209 Cr
TTM · standalone
EPS
₹25.98
TTM · standalone
RETURN ON EQUITY
20.0%
TTM · standalone
P/E
32.7x
Q4 FY26 · standalone
EV/EBITDA
22.3x
Q4 FY26 · standalone
EBITDA MARGIN
36.9%
TTM · standalone
NET PROFIT MARGIN
26.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Supriya Lifescience LimitedSUPRIYA | 4,613 | 32.74 | 22.28 | 18.9% | 36.9% | 20.0% | 25.6% | +18.0% |
FDC LimitedFDC | 5,431 | 24.39 | 14.83 | 3.0% | 21.2% | 12.1% | 15.8% | -15.0% |
Innova Captab LimitedINNOVACAP | 3,954 | 41.08 | 24.48 | 31.1% | 15.4% | 14.2% | 16.3% | +11.7% |
SMS Pharmaceuticals LimitedSMSPHARMA | 3,722 | 34.20 | 21.96 | 13.3% | 20.3% | 15.1% | 16.0% | +57.8% |
Sun Pharma Advanced Research Company LimitedSPARC | 3,663 | 5.23 | 5.39 | 2518.3% | 85.7% | 903.1% | 488.1% | +53.6% |
Zota Health Care LimitedZOTA | 3,596 | -57.68 | 160.70 | 83.9% | 4.8% | -21.7% | 8.7% | +16.9% |
As of Q4 FY26
Financials
Supriya Lifescience Limited
NSE: SUPRIYA · Pharmaceuticals
Snapshot
Unlock Supriya Lifescience Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Supriya Lifescience Limited is a Mumbai-based pharmaceutical company specialising in the research, development, and manufacturing of active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio including anti-histamine, anti-asthmatic, and analgesic therapeutic segments for global markets.
Business Model
The company generates revenue primarily through the large-scale production and sale of bulk drugs and APIs to international pharmaceutical manufacturers. It leverages its research and development capabilities to supply a wide range of therapeutic categories and chemical derivatives.
Growth Outlook
Growth is driven by the expansion of its API product pipeline and the strengthening of its global distribution network. The company continues to focus on enhancing its manufacturing capabilities to meet increasing international demand for specialised pharmaceutical ingredients.
Key Risks
- Regulatory Compliance. The company is subject to stringent inspections by global health authorities, where any failure to meet quality standards could lead to export restrictions.
- Raw Material Price Volatility. Fluctuations in the costs of key starting materials and chemical intermediates can significantly impact operating margins.
- Foreign Exchange Risk. As a significant portion of revenue is derived from international markets, the company is exposed to currency fluctuations between the Indian Rupee and foreign currencies.
- Geopolitical and Trade Barriers. Changes in international trade policies or import regulations in key markets could disrupt the company's supply chain and sales volume.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Supriya Lifescience Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹828 Cr
TTM · standalone
NET PROFIT
₹209 Cr
TTM · standalone
EPS
₹25.98
TTM · standalone
RETURN ON EQUITY
20.0%
TTM · standalone
P/E
32.7x
Q4 FY26 · standalone
EV/EBITDA
22.3x
Q4 FY26 · standalone
EBITDA MARGIN
36.9%
TTM · standalone
NET PROFIT MARGIN
26.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26